Managing Neuromyelitis Optica Spectrum Disorders: How Can You Achieve Long-Term Relapse-Free Outcomes in Practice?
Podcast 2
Post-Test/Evaluation

Questions marked with a * are required

19%

Contact Information

First Name

Last Name

Email Address

Credentials/Degree (MD, DO, RN, etc.)

Date of Participation

Discovery of which of the following antibodies revolutionized the pathogenesis of NMOSD?

A. Myelin oligodendrocyte glycoprotein (MOG)

B. Aquaporin-4 (AQP4)

C. Serum glial fibrillary acidic protein (sGFAP)

D. Vimentin

Which of the following is true regarding the following FDA-approved treatment for NMOSD?

A. Eculizumab is a complement inhibitor, a monoclonal antibody that is given intravenously and activates the terminal complement component C5

B. Inebilizumab is a B-cell-depleting therapy and an intravenous monoclonal antibody that targets CD20

C. Satralizumab is a monoclonal antibody that is administered subcutaneously and targets the interleukin-6 receptor

D. Rituximab is a B-cell-depleting monoclonal antibody that targets CD20